sur NICOX (EPA:COX)
Nicox's ZERVIATE Reaches Chinese Market Through Ocumension Partnership
Nicox SA has announced the first commercial sale of ZERVIATE in China, facilitated by its partner Ocumension Therapeutics. This eye drop, containing the antihistamine cetirizine, addresses ocular itching linked to allergic conjunctivitis. Approved in China in September 2024, ZERVIATE fills a significant medical gap, particularly benefiting young children.
This sale marks a significant step in the partnership between Nicox and Ocumension, which commenced in 2018. Ocumension has an enhanced leadership position in China’s ophthalmology sector, owing to strategic acquisitions and efficient operations, including a swift manufacturing campaign. The collaboration also covers another key development, NCX 470, currently in Phase 3 trials in China.
The ZERVIATE agreement allows Nicox to earn up to $17.2 million in sales milestones and royalties between 5% and 9% on net sales, strengthening its revenue stream.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NICOX